Keywords
Hypersensitivity reactions to drugs
Adverse reactions to drugs
Delayed drug reactions
Abstract
Background: Adverse drug reactions are defined as unexpected reactions, either derived from the pharmacokinetics of the treatment (Type A) or as a host immune response (Type B), resulting in harmful or undesirable manifestations in the patient following the administration of pharmacological therapy. Type B reactions are less defined and are considered a result of hypersensitivity to pharmacological treatment, categorized as immediate (within 1 to 6 hours after exposure) and delayed or non-immediate (occurring 6 hours after exposure).
Objective: A review to describe the immunological mechanisms of delayed hypersensitivity reactions to drugs.
Methods: A search of major medical databases on delayed hypersensitivity reactions to drugs was conducted. The review was limited to articles published in the period between 2013 and 2023, taking into consideration articles written in English and Spanish.
Results: The terms defining delayed hypersensitivity reactions to drugs, their classification, clinical manifestations, diagnosis, treatment algorithms, and prognosis.
Conclusion: Adverse drug reactions represent a challenge for the specialist physician, with a complex pathophysiology. A prompt diagnosis and treatment focused on the drug phenotype and its immunological expression are required to provide a multidisciplinary approach.
Keywords: Drug allergy; Hypersensitivity reactions to drugs; Adverse reactions to drugs; Delayed drug reactions.
References
Zazzara MB, Palmer K, Vetrano DL, et al. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med 2021; 12 (3): 463-473. doi: 10.1007/s41999-021-00481-9
Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy Eur J Allergy Clin Immunol 2019; 74 (8): 1457-1471. doi: 10.1111/all.13765
Dykewicz MS, Lam JK. Drug Hypersensitivity Reactions. Med Clin North Am 2020; 104 (1): 109-128. doi: 10.1016/j.mcna.2019.09.003
Böhm R, Proksch E, Schwarz T, et al. Drug Hypersensitivity. Dtsch Arztebl Int 2018; 115 (29-30): 501-512. doi: 10.3238/arztebl.2018.0501
Redwood AJ, Pavlos RK, White KD, et al. HLAs: Key regulators of T-cell-mediated drug hypersensitivity. Hla 2018; 91 (1): 3-16. doi: 10.1111/tan.13183
Baruffi FY, Venkatesh KP, Nelson KN, Powell A, Santos DM, Ehrlich A. Systemic Contact Dermatitis: A review. Dermatol Clin 2020; 38 (3): 379-388. doi: 10.1016/j.det.2020.02.008
Nguyen HL, Yiannias JA. Contact Dermatitis to Medications and Skin Products. Clin Rev Allergy Immunol 2019; 56 (1): 41-59. doi: 10.1007/s12016-018-8705-0
Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58 (1): 1-21. doi: 10.1016/j.jaad.2007.07.050
Pinheiro V, Pestana C, Pinho A, et al. Occupational allergic contact dermatitis caused by antibiotics in healthcare workers - relationship with non-immediate drug eruptions. Contact Dermatitis. 2018;78(4):281-286. doi:10.1111/cod.12960
Minciullo PL, Imbesi S, Tigano V, et al. Airborne contact dermatitis to drugs. Allergol Immunopathol (Madr) 2013; 41 (2): 121-126. doi: 10.1016/j.aller.2012.01.004
Groot AC. Systemic allergic dermatitis (systemic contact dermatitis) from pharmaceutical drugs: A review. Contact Dermatitis 2022; 86 (3): 145-164. doi: 10.1111/cod.14016
Kulberg A, Schliemann S, Elsner P. Contact dermatitis as a systemic disease. Clin Dermatol. 2014;32(3):414-419. doi: 10.1016/j.clindermatol.2013.11.008
Anderson HJ, Lee JB. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. Medicina (B Aires) 2021; 57 (9): 925. doi: 10.3390/medicina57090925
Flowers H, Brodell R, Brents M, et al. Fixed Drug Eruptions: Presentation, Diagnosis, and Management. South Med J 2014; 107 (11): 724-727. doi: 10.14423/SMJ.0000000000000195
Valeyrie-Allanore L, Lebrun-Vignes B, Bensaid B, et al. Fixed pigmented erythema: Epidemiology, physiopathology, clinical features, differential diagnosis, and therapeutic management). Ann Dermatol Venereol 2015; 142 (11): 701-706. doi: 10.1016/j.annder.2015.07.010
M. Chaabani, F. Ben Salem, A. Zaouak, S. Ben Jannet, H. Hammami SF. Genital involvement during fixed bullous pigment erythema. Ann Dermatol Venereol 2018; 145 (4S): A55.
Pai V, Kikkeri N, Athanikar S, Bhandari P, et al. Retrospective analysis of fixed drug eruptions among patients attending a tertiary care center in Southern India. Indian J Dermatology Venereol Leprol 2014; 80 (2): 194. doi: 10.4103/0378-6323.129435
Patell RD, Dosi R V, Shah PC, et al. Widespread bullous fixed drug eruption. Case Reports 2014; 2014. doi: 10.1136/bcr-2013-200584
Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008; 158 (6): 1230-1238. doi: 10.1111/j.1365-2133.2008.08516.x
Heng YK, Yew YW, Lim DSY, et al. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatology Venereol. 2015;29(8):1539-1544. doi:10.1111/jdv.12919
Gavin M, Sharp L, Walker K, et al. Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome. Baylor Univ Med Cent Proc 2019; 32 (4): 601-602. doi: 10.1080/08998280.2019.1644147
Sharma L, Agarwal R, Chopra A, et al. A cross-sectional observational study of clinical spectrum and prevalence of fixed food eruption in a tertiary care hospital. Indian Dermatol Online J 2020; 11 (3): 361. doi: 10.4103/idoj.IDOJ_340_19
Ben Fadhel N, Chaabane A, Ammar H, et al. Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis 2019; 81 (5): 336-340. doi: 10.1111/cod.13351
Cho Y-T, Lin J-W, Chen Y-C, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 2014; 70 (3): 539-548. doi: 10.1016/j.jaad.2013.11.015
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol 2018; 54 (1): 177-184. doi: 10.1007/s12016-017-8667-7
Samim F, Auluck A, Zed C, et al. Erythema Multiforme. Dent Clin North Am 2013; 57 (4): 583-596. doi: 10.1016/j.cden.2013.07.001
Siedner-Weintraub Y, Gross I, David A, et al. Paediatric Erythema Multiforme: Epidemiological, Clinical and Laboratory Characteristics. Acta Derm Venereol 2017; 97 (4): 489-492. doi: 10.2340/00015555-2569
Soares A, Sokumbi O. Recent Updates in the Treatment of Erythema Multiforme. Medicina (B Aires) 2021; 57 (9): 921. doi: 10.3390/medicina57090921
Trayes KP, Love G, Studdiford JS. Erythema Multiforme: Recognition and Management. Am Fam Physician 2019; 100 (2): 82-88.
Grünwald P, Mockenhaupt M, Panzer R, et al. Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment. JDDG J der Dtsch Dermatologischen Gesellschaft 2020; 18 (6): 547-553. doi: 10.1111/ddg.14118
Goldman RD. Erythema multiforme in children. Can Fam Physician 2022; 68 (7): 507-508. doi: 10.46747/cfp.6807507
Suástegui-Rodríguez I, Campos-Jiménez KI, Domínguez-Cherit J, et al. [Adverse cutaneous reactions to drugs]. Rev Med Inst Mex Seguro Soc 2018; 56 (1): 64-70.
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Sel 2017; 1 (1): 96-108. doi: 10.5414/ALX01508E
Muñoz-Hiraldo ME, Plaza-Almeida JAAJ. Guía de Algoritmos en Pediatría de Atención Primaria. Exantemas maculopapulosos. AEPap Published 2015. https://algoritmos.aepap.org/adjuntos/exantemas_maculopapulosos.pdf
Patel T, Thakkar S, Sharma D. Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatol Online J 2014; 5 (6): 76. doi: 10.4103/2229-5178.146165
Kloypan C, Koomdee N, Satapornpong P, et al. A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals 2021; 14 (11): 1077. doi: 10.3390/ph14111077
Perello MI, de Maria-Castro A, Nogueira-Arraes AC, et al. Severe cutaneous adverse drug reactions: diagnostic approach and genetic study in a Brazilian case series. Eur Ann Allergy Clin Immunol 2022; 54 (05): 207. doi: 10.23822/EurAnnACI.1764-1489.193
Cortés Pater S, Abbruzzesse M, Barbini C, Busso C. Exantema Intertriginoso y Flexural Simétrico Por Fármacos: Presentación de Un Caso; 2022. doi: 10.21840/siic/170387
Rodríguez CA PM. ¿Exantema intertriginoso y flexural simétrico relacionado con fármacos o síndrome del babuino? 2022; 20 (4): 453-458.
Tziotzios C, Lee JYW, Brier T, et al. Lichen planus and lichenoid dermatoses. J Am Acad Dermatol 2018; 79 (5): 789-804. doi: 10.1016/j.jaad.2018.02.010
Cheraghlou S, Levy LL. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions. Clin Dermatol. 2020;38(6):679-692. doi:10.1016/j.clindermatol.2020.06.010
Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ, Bieber K. Lichen Planus. Front Med. 2021;8. doi:10.3389/fmed.2021.737813
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol 2015; 73 (5): 843-848. doi: 10.1016/j.jaad.2015.07.017
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR). Br J Dermatol 2007; 157 (5): 989-996. doi: 10.1111/j.1365-2133.2007.08156.x
Bhat Y, Akhtar S, Ahmad M, et al. Etiopathological and clinical study of acute generalized exanthematous pustulosis: Experience from a tertiary care hospital in North India. Indian Dermatol Online J 2020; 11 (3): 391. doi: 10.4103/idoj.IDOJ_232_19
Gualtieri B, Solimani F, Hertl M, et al. Interleukin 17 as a therapeutic target of acute generalized exanthematous pustulosis (AGEP). J Allergy Clin Immunol Pract 2020; 8 (6): 2081-2084.e2. doi: 10.1016/j.jaip.2020.01.045
Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatology 2022; 158 (2): 176. doi: 10.1001/jamadermatol.2021.5390
Parisi R, Shah H, Navarini AA, et al. Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management. Am J Clin Dermatol 2023; 24 (4): 557-575. doi: 10.1007/s40257-023-00779-3
De A, Rajagopalan M, Sarda A, et al. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian J Dermatol 2018; 63 (1): 30. doi: 10.4103/ijd.IJD_582_17
Calle AM, Aguirre N, Ardila JC, et al. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J 2023; 16 (3): 100673. doi: 10.1016/j.waojou.2022.100673
Mugwagwa AN, Fischer R, Zailan I. HLA‐B*5801: a genetic susceptibility to allopurinol‐induced DRESS. Med J Aust 2016; 204 (4): 159-160. doi: 10.5694/mja15.01113
Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012; 67 (11): 1338-1346. doi: 10.1111/all.12008
Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin Dermatol 2019; 20 (2): 217-236. doi: 10.1007/s40257-018-00416-4
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169 (5): 1071-1080. doi: 10.1111/bjd.12501
Sasidharanpillai S, Ajithkumar K, Jishna P, et al. RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): A comparative analysis. Indian Dermatol Online J 2022; 13 (1): 40. doi: 10.4103/idoj.idoj_196_21
Pavón-Romero GF, Gutiérrez-Quiroz KV, Ramírez-Jiménez F, et al. DRESS, una reacción alérgica no mediada por IgE. Rev la Fac Med 2023; 66 (2): 7-19. doi: 10.22201/fm.24484865e.2023.66.2.02
Roujeau J-C, Haddad C, Paulmann M, et al. Management of Nonimmediate Hypersensitivity Reactions to Drugs. Immunol Allergy Clin North Am 2014; 34 (3): 473-487. doi: 10.1016/j.iac.2014.04.012
Bommersbach TJ, Lapid MI, Leung JG, et al. Management of Psychotropic Drug–Induced DRESS Syndrome: A Systematic Review. Mayo Clin Proc 2016; 91 (6): 787-801. doi: 10.1016/j.mayocp.2016.03.006
Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol 2017; 137 (6): 1240-1247. doi: 10.1016/j.jid.2017.01.031
Frantz R, Huang S, Are A, Motaparthi K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (B Aires) 2021; 57 (9): 895. doi: 10.3390/medicina57090895
Deshpande P, Hertzman RJ, Palubinsky AM, et al. Immunopharmacogenomics: Mechanisms of HLA‐Associated Drug Reactions. Clin Pharmacol Ther 2021; 110 (3): 607-615. doi: 10.1002/cpt.2343
Goodman CW, Brett AS. Race and Pharmacogenomics—Personalized Medicine or Misguided Practice? JAMA 2021; 325 (7): 625. doi: 10.1001/jama.2020.25473
Gibson A, Deshpande P, Campbell CN, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol 2023; 151 (2): 289-300.e4. doi: 10.1016/j.jaci.2022.12.005
Kuijper EC, French LE, Tensen CP, et al. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatology Venereol 2020; 34 (9): 1957-1971. doi: 10.1111/jdv.16339
Brandt C, McGuire L, Uetrecht J. Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention. Epilepsy Behav 2021; 117: 107844. doi: 10.1016/j.yebeh.2021.107844
Ergen EN, Hughey LC. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology 2017; 153 (12): 1344. doi: 10.1001/jamadermatol.2017.3957
Yorulmaz A, Akın F, Sert A, et al. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol 2018; 37 (5): 1389-1394. doi: 10.1007/s10067-017-3777-4
Netchiporouk E DSS. Severe Serum Sickness-Like Reaction: Challenges in Diagnosis and Management. J Clin Exp Dermatol Res 2015; 06 (03). doi: 10.4172/2155-9554.1000279
Del Pozzo-Magaña BR, Abuzgaia A, Murray B, et al. Paediatric serum sickness-like reaction: A 10-year retrospective cohort study. Paediatr Child Health 2021; 26 (7): 428-435. doi: 10.1093/pch/pxab003
Chung B-S, Liu W-T, Chen P-W. Serum Sickness-Like Reactions After Pneumococcal Vaccination. Cureus 2021; 13 (9). doi: 10.7759/cureus.17877
Peng B, Wei M, Zhu F-C, Li J-X. The vaccines-associated Arthus reaction. Hum Vaccin Immunother 2019; 15 (11): 2769-2777. doi: 10.1080/21645515.2019.1602435
Misra D, Patro P, Sharma A. Drug-induced vasculitis. Indian J Rheumatol 2019; 14 (5): 3. doi: 10.4103/0973-3698.272156
da Silva Cendon Duran C, da Paz AS, Barreto Santiago M. Vasculitis induced by biological agents used in rheumatology practice: A systematic review. Arch Rheumatol 2022; 37 (2): 300-310. doi: 10.46497/ArchRheumatol.2022.9049
Fathallah N, Ouni B, Mokni S, et al. [Drug-induced vasculitis]. Therapie 2019; 74 (3): 347-354. doi: 10.1016/j.therap.2018.07.005
Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. Front Immunol 2021; 12. doi: 10.3389/fimmu.2021.762006
Torres FA, González LA, Vásquez GM, et al. Ergotism, a relatively unknown mimic of vasculitis: A case report and review of literature. Rev Colomb Reumatol 2020; 27 (4): 303-307. doi: 10.1016/j.rcreu.2020.02.002
Younger DS, Carlson A. Dermatologic Aspects of Systemic Vasculitis. Neurol Clin 2019; 37 (2): 465-473. doi: 10.1016/j.ncl.2019.01.017
Vayne C, Guéry E-A, Rollin J, et al. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. J Clin Med 2020; 9 (7): 2212. doi: 10.3390/jcm9072212
Rattay B, Benndorf RA. Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous. Front Pharmacol 2021; 12. doi: 10.3389/fphar.2021.727717
Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 2017; 177 (2): 208-220. doi: 10.1111/bjh.14654
Curtis BR. Non–chemotherapy drug–induced neutropenia: key points to manage the challenges. Hematology 2017; 2017 (1): 187-193. doi: 10.1182/asheducation-2017.1.187
Marini I, Uzun G, Jamal K, et al. Treatment of drug-induced immune thrombocytopenias. Haematologica 2022; 107 (6): 1264-1277. doi: 10.3324/haematol.2021.279484
Goossens RA. Allergic Contact Dermatitis from the Vehicle Components of Topical Pharmaceutical Products. Immunol Allergy Clin North Am 2014; 34 (3): 663-670. doi: 10.1016/j.iac.2014.04.010
Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatology 2010; 20 (4): 461-464. doi: 10.1684/ejd.2010.0980
Byrd RC, Mournighan KJ, Baca-Atlas M, et al. Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Reports 2018; 4 (9): 953-955. doi: 10.1016/j.jdcr.2018.07.013
Karagöl C, Ceran A, Güngör A, et al. Baboon Syndrome Associated with Ampicillin Sulbactam. J Allergy Clin Immunol Pract 2018; 6 (6): 2106-2107. doi: 10.1016/j.jaip.2018.02.011
Sapadin YK, Mermelstein E, Phelps RG, et al. COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature. Vaccines 2023; 11 (2): 438. doi: 10.3390/vaccines11020438
De A, Das S, Sarda A, et al. Acute generalised exanthematous pustulosis: An update. Indian J Dermatol 2018; 63 (1): 22. doi: 10.4103/ijd.IJD_581_17
Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78 (4): 611-613. doi: 10.1053/j.ajkd.2021.06.016
Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors—a systematic review. Clin Rheumatol 2018; 37 (9): 2579-2584. doi: 10.1007/s10067-018-4177-0
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Revista Alergia México